Total Payments
$3,876
2024 Payments
$1,291
Companies
27
Transactions
190
Medicare Patients
309
Medicare Billing
$22,348
Payment Breakdown by Category
Food & Beverage$3,876 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,876 | 190 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alkermes, Inc. | $584.62 | 27 | $0 (2024) |
| Indivior Inc. | $471.56 | 24 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $405.85 | 18 | $0 (2024) |
| Lundbeck LLC | $322.94 | 15 | $0 (2024) |
| Braeburn Inc. | $313.78 | 14 | $0 (2024) |
| Orexo US, Inc. | $260.78 | 15 | $0 (2022) |
| ABBVIE INC. | $202.55 | 10 | $0 (2024) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $185.60 | 10 | $0 (2024) |
| Tris Pharma Inc | $178.06 | 10 | $0 (2024) |
| ITI, Inc. | $120.39 | 7 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,291 | 63 | Alkermes, Inc. ($204.80) |
| 2023 | $1,017 | 47 | Alkermes, Inc. ($186.81) |
| 2022 | $695.45 | 38 | Alkermes, Inc. ($193.01) |
| 2021 | $362.37 | 19 | Neurocrine Biosciences, Inc. ($92.55) |
| 2020 | $216.78 | 12 | Indivior Inc. ($99.29) |
| 2019 | $111.69 | 3 | Avanir Pharmaceuticals, Inc. ($78.32) |
| 2018 | $85.93 | 5 | Orexo US, Inc. ($50.28) |
| 2017 | $96.51 | 3 | ACADIA Pharmaceuticals Inc ($61.66) |
All Payment Transactions
190 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $23.24 | General |
| Category: Opioid Use Disorder | ||||||
| 12/18/2024 | IRONSHORE PHARMACEUTICALS INC. | JORNAY PM (Drug) | Food and Beverage | Cash or cash equivalent | $17.25 | General |
| Category: CENTRAL NERVOUS SYSTEM STIMULANT | ||||||
| 12/17/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $28.27 | General |
| Category: OUD | ||||||
| 12/11/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $128.10 | General |
| Category: CNS | ||||||
| 12/10/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $15.33 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $5.19 | General |
| Category: Opioid Use Disorder | ||||||
| 11/21/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $6.48 | General |
| Category: Opioid Use Disorder | ||||||
| 11/20/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $22.13 | General |
| Category: PSYCHIATRY | ||||||
| 11/19/2024 | IRONSHORE PHARMACEUTICALS INC. | JORNAY PM (Drug) | Food and Beverage | Cash or cash equivalent | $14.11 | General |
| Category: CENTRAL NERVOUS SYSTEM STIMULANT | ||||||
| 11/13/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $24.21 | General |
| Category: PSYCHIATRY | ||||||
| 11/06/2024 | Alkermes, Inc. | VIVITROL (Drug) | Food and Beverage | In-kind items and services | $18.16 | General |
| Category: CNS | ||||||
| 10/23/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.33 | General |
| Category: NEUROSCIENCE | ||||||
| 10/22/2024 | IRONSHORE PHARMACEUTICALS INC. | JORNAY PM (Drug) | Food and Beverage | Cash or cash equivalent | $15.52 | General |
| Category: CENTRAL NERVOUS SYSTEM STIMULANT | ||||||
| 10/16/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug), ABILIFY MAINTENA | Food and Beverage | In-kind items and services | $23.17 | General |
| Category: PSYCHIATRY | ||||||
| 10/15/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $19.58 | General |
| Category: PSYCHIATRY | ||||||
| 10/08/2024 | Tris Pharma Inc | Dyanavel XR (Drug) | Food and Beverage | In-kind items and services | $13.51 | General |
| Category: ADHD | ||||||
| 10/02/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $29.55 | General |
| Category: OUD | ||||||
| 09/25/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $23.21 | General |
| Category: Opioid Use Disorder | ||||||
| 09/24/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: NEUROSCIENCE | ||||||
| 09/18/2024 | Alkermes, Inc. | VIVITROL (Drug) | Food and Beverage | In-kind items and services | $15.79 | General |
| Category: CNS | ||||||
| 09/11/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $20.30 | General |
| Category: PSYCHIATRY | ||||||
| 09/03/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $15.61 | General |
| Category: Opioid Use Disorder | ||||||
| 08/21/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.69 | General |
| Category: NEUROSCIENCE | ||||||
| 07/31/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $26.20 | General |
| Category: PSYCHIATRY | ||||||
| 07/30/2024 | Tris Pharma Inc | Dyanavel XR (Drug) | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: ADHD | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 2 | 255 | 255 | $5,858 | $5,380 |
| 2020 | 4 | 54 | 208 | $34,267 | $16,968 |
Total Patients
309
Total Services
463
Medicare Billing
$22,348
Procedure Codes
6
All Medicare Procedures & Services
6 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 0011A | Adm sarscov2 100mcg/0.5ml1st | Office | 2021 | 162 | 162 | $3,067 | $2,816 | 91.8% |
| 0012A | Adm sarscov2 100mcg/0.5ml2nd | Office | 2021 | 93 | 93 | $2,791 | $2,565 | 91.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 19 | 98 | $18,646 | $8,240 | 44.2% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2020 | 12 | 44 | $7,788 | $5,021 | 64.5% |
| 80307 | Testing for presence of drug | Office | 2020 | 12 | 53 | $6,360 | $3,285 | 51.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 11 | 13 | $1,473 | $421.82 | 28.6% |
About Dr. David Kaplan, MD
Dr. David Kaplan, MD is a Addiction Medicine healthcare provider based in Greensboro, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1134208994.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Kaplan, MD has received a total of $3,876 in payments from pharmaceutical and medical device companies, with $1,291 received in 2024. These payments were reported across 190 transactions from 27 companies. The most common payment nature is "Food and Beverage" ($3,876).
As a Medicare-enrolled provider, Kaplan has provided services to 309 Medicare beneficiaries, totaling 463 services with total Medicare billing of $22,348. Data is available for 2 years (2020–2021), covering 6 distinct procedure/service records.
Ad
Practice Information
- Specialty Addiction Medicine
- Other Specialties Addiction Medicine, Family Medicine
- Location Greensboro, NC
- Active Since 11/03/2006
- Last Updated 02/17/2025
- Taxonomy Code 207QA0401X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1134208994
Products in Payments
- SUBLOCADE (Drug) $471.56
- ARISTADA (Drug) $315.52
- BRIXADI (Drug) $313.78
- CAPLYTA (Drug) $305.99
- REXULTI (Drug) $296.21
- ABILIFY MAINTENA (Drug) $295.31
- VRAYLAR (Drug) $202.55
- Zubsolv (Drug) $199.70
- Dyanavel XR (Drug) $178.06
- LYBALVI (Drug) $172.55
- ABILIFY ASIMTUFII (Drug) $137.27
- Azstarys (Drug) $118.02
- INGREZZA (Drug) $114.27
- QELBREE (Drug) $80.06
- NUEDEXTA (Drug) $78.32
- SYMJEPI (Drug) $66.29
- NUPLAZID (Drug) $61.66
- Lucemyra (Drug) $56.10
- Vivitrol (Drug) $51.68
- JORNAY PM (Drug) $46.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.